Bortezomib-induced histiocytoid Sweet syndrome.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 19231647.
- Also identified by DOI 10.1016/j.jaad.2008.09.007.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma, has been reported to be associated with Sweet syndrome. However, careful review of the histopathology of the first reported case and our case revealed similar histologic and immunohistochemical findings (a mononuclear dermal infiltrate) and not the usual neutrophilic infiltrate of Sweet syndrome. We suggest that the dermatitis induced by bortezomib is best classified as "histiocytoid Sweet syndrome."
Medical subject headings
- Boronic Acids
- Drug Eruptions
- Multiple Myeloma
- Protease Inhibitors
- Pyrazines
- Sweet Syndrome